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Abstract
Gene expression programs determine cell fate in embryonic development and their dysre-
gulation results in disease. Transcription factors (TFs) control gene expression by binding to
enhancers, but how TFs select and activate their target enhancers is still unclear. HOX TFs
share conserved homeodomains with highly similar sequence recognition properties, yet
they impart the identity of different animal body parts. To understand how HOX TFs control
their specific transcriptional programs in vivo, we compared HOXA2 and HOXA3 binding
profiles in the mouse embryo. HOXA2 and HOXA3 directly cooperate with TALE TFs and
selectively target different subsets of a broad TALE chromatin platform. Binding of HOX and
tissue-specific TFs convert low affinity TALE binding into high confidence, tissue-specific
binding events, which bear the mark of active enhancers. We propose that HOX paralogs,
alone and in combination with tissue-specific TFs, generate tissue-specific transcriptional
outputs by modulating the activity of TALE TFs at selected enhancers.
Author summary
The different anatomical features that develop along the animal body axis are determined
by HOX transcription factors. Each member of the HOX family appears in a well-defined
territory of the developing embryo, and instruct a specific gene expression program. In
stark contrast to their specificity in vivo, which is central to developmental programs,
HOX transcription factors display highly similar sequence recognition properties in vitro.
To understand how HOX transcription factors control their specific transcriptional pro-
grams in vivo, we compared HOXA2 and HOXA3 binding profiles in the mouse embryo.
We find that HOXA2 and HOXA3 occupy a large set of high-confidence, non-overlap-
ping genomic regions, that are also bound by three aminoacid loop extension (TALE)
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transcription factors. We identify three main determinants of HOX paralog-selective
binding: recognition of unique variants of the HOX-PBX motif, differential affinity at
shared HOX-PBX motifs and, additionally, contribution of tissue-specific transcription
factors. These mechanisms result in high-confidence, cooperative HOX-TALE binding at
different genomic locations, which bear the mark of active enhancers. We propose that
HOX paralogs operate, alone and in concert with tissue-specific transcription factors, to
switch on TALE function at selected enhancers.
Introduction
Gene expression programs instruct and maintain cell fate in embryonic development and adult
tissue homeostasis. Transcription factors (TFs) control gene expression by binding to enhancers
[1,2]. However, we still have no clear idea of how TFs select their precise sets of target enhanc-
ers. While TFs contain DNA binding domains which recognize DNA in a sequence-specific
manner, these interactions are typically insufficient to direct a TF to its functional targets.
Transcriptional regulation is mediated by TFs working together, rather than in isolation.
The widespread occurrence of collaborative TF binding is imposed by chromatin. A single TF
cannot easily compete with nucleosomes to access DNA, but multiple TFs that recognize
closely spaced binding sites can effectively displace nucleosomes and indirectly facilitate each
other’s binding [3,4]. Such indirect cooperativity can also result in TFs recognizing low affinity
sites, i.e. sites that deviate from their optimal consensus in vitro [5]. Recent observations indi-
cate that TF cooperativity does not end at binding enhancers: clusters of enhancer-bound TFs
concentrate co-activators and other nuclear factors via dynamic fuzzy interactions, driven by
their intrinsically disordered regions (IDRs). IDRs function in molecular recognition and
mediate the interaction with a diversity of regulatory proteins [6,7] to promote the liquid-liq-
uid phase transition associated with gene activation [8]. Thus, the formation, on DNA seg-
ments, of regulatory complexes made of different combinations of factors, is key to activation
of gene expression. These distinct combinations of TFs produce virtually inexhaustible fla-
vours of gene expression and cell fate [1].
HOX TFs provide an ideal model to explain how TFs select their target enhancers to direct
specific transcriptional programs in vivo. They contain a homeodomain (HD), a highly con-
served DNA binding moiety shared by hundreds of TFs [9,10]. HD display highly similar
sequence recognition properties and bind the same core of four-base-pair sequence TAAT [11],
yet HOX TFs function to establish the identity of entirely different body parts along the antero–
posterior axis of all bilaterian animals [12,13]. In mammals, there are 39 Hox genes, classified
into anterior (HOX1-2), central (HOX3–8), and posterior (HOX 9–13) paralog groups [14].
HOX paralogs occupy sequential positions along the chromosome, which are faithfully main-
tained across evolution [15]. This translates into precise HOX expression codes at different lev-
els of the antero-posterior axis, conferring specific spatial and temporal coordinates to each cell.
HOX association with three amino acid loop extension (TALE) HD TFs PBX, and PBX part-
ner MEIS, is a widely accepted mechanism underlying HOX target specificity [10,16,17]. HOX--
TALE cooperativity increases the affinity and sequence selectivity of HOX TFs in vitro [16]. In
vivo, HOXA2 extensively binds with TALE TFs [18] and Ubx and Hth (fly homologs to verte-
brate central HOX and MEIS respectively) co-localize in active nuclear microenvironments,
suggesting that their interaction may be critical to trigger phase separation [19]. Interestingly,
Hox binding selectivity can be observed in the absence of TALE TFs, and is strongly associated
with chromatin accessibility [20]. Although the concept of HOX and TALE interaction is long
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established, we still understand relatively little about the extent and functional significance of
HOX-TALE association in vivo, where compaction of DNA into chromatin and the distribution
of sequence-specific TFs (cell-specific and tissue-specific, but also ubiquitous) can considerably
affect TF binding to DNA. Also, how the association with fairly ubiquitous proteins eventually
translates into HOX paralog-specific transcriptional outputs in vivo, remains unclear.
To understand how HOX TFs execute their specific functions to impart different segmental
identity in vivo, we compared binding of HOXA2 and HOXA3, an anterior and a central HOX
proteins, in the physiological tissues where these TFs are active. Branchial arches (BA) are
blocks of embryonic tissues that merge to form the face and the neck in vertebrates. The sec-
ond and third branchial arch (BA2 and BA3) are the main domains of HOXA2 and HOXA3
expression respectively, and the embryonic areas most affected by inactivation of Hoxa2 and
Hoxa3 in mouse [21–23]. We find that, in the BAs, HOXA2 and HOXA3 occupy a large set of
high-confidence, non-overlapping genomic regions, that are also bound by TALE TFs. We
identify three main determinants of HOX paralog-selective binding, resulting in high-confi-
dence cooperative HOX-TALE binding at different genomic locations: recognition of unique
variants of the HOX-PBX motif, differential affinity at shared HOX-PBX motifs and, addi-
tional contribution of tissue-specific TFs. We propose that HOX paralogs operate, alone and
in concert with tissue-specific TFs, to switch on TALE function at selected enhancers.
Results
HOXA2 and HOXA3 control diverse processes by targeting different
regions of the genome
HOX TFs direct highly specific gene expression programs in vivo, but recognize very similar
DNA sequences in vitro. However, it remains to be determined if HOX specificity of action
reflects specificity of binding across the genome in vivo, i.e. the binding of paralog HOX TFs to
distinct target regions. To establish this, we compared HOXA2 and HOXA3 binding profiles in
their physiological domains of expression in the mouse embryo. BAs display an antero-posterior
gradient of HOX expression, which replicates Hox gene positions on the chromosome (Fig 1A
and 1B): BA1 does not express any Hox gene, BA2 expresses Hox2 paralogs, BA3 Hox3 paralogs,
etc. We previously characterized HOXA2 binding in BA2 [18]; here, we profiled HOXA3 binding
in BA3-4-6 (hereafter referred to as posterior branchial arches, PBA), the embryonic tissues
immediately posterior to the BA2 (identified by the expression of Hox paralogs 3–5, Fig 1A and
1B). Using a HOXA3-specific antibody (S1A Fig), we identified 848 peaks with fold enrichment
(FE)�10, which largely contained a second biological replicate (S1B Fig; S1 Table). TALE TFs
(PBX and MEIS) display cooperative binding with HOX and increase HOX binding specificity in
vitro [16]. De novo motif discovery [24] identified HOX-PBX recognition sequence as the top
enriched motif in HOXA3 peaks and uncovered MEIS binding site in the top three sequence
motifs (S1C Fig). HOXA3 recognition sites in PBA correspond to HOXA2 motifs in BA2 (S1D
and S1E Fig); moreover, the frequency of HOX-PBX motifs is comparable across HOXA2 and
HOXA3 peaks (S1F Fig). HOX peaks without canonical HOX-PBX consensus motifs, contain
similar (i.e. 1nt mismatch), potential low affinity variants of HOX-PBX sites (S1F Fig). The occur-
rence of high affinity sites (perfect matches) positively correlates with peak FE, and is highest in
top HOXA2 and HOXA3 peaks. Low affinity sites (1 mismatch allowed in TGATNNAT) show
the opposite trend and occur with higher frequency in lower confidence binding events (S1G Fig).
We overlapped HOXA2 binding in BA2 (S2 Table) with HOXA3 binding in PBA. About
half of HOXA3 peaks are contained in the larger HOXA2 datasets (Fig 1C and 1D). When
comparing the same number of peaks for both datasets, ranked by FE, we observed an increas-
ing overlap at lower confidence peaks (Fig 1E), suggesting that HOXA2 and HOXA3 select
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different sites when binding with higher affinity and are more promiscuous at lower binding
levels. Functional association of HOXA3-specific peaks in PBA and HOXA2-specific peaks in
BA2 [25] (Fig 1F and 1G) highlights distinct biological processes and mouse phenotypes,
including abnormal middle ear, sphenoid, temporal and squamosal bone morphologies,
whose morphogenesis is controlled by HOXA2 [21,22]. Remarkably, genes dysregulated in the
HOXA2 mutant [26] are significantly represented in the top biological processes and mouse
phenotypes associated with HOXA2 peaks (S1H Fig). In contrast HOXA3-specific binding is
almost exclusively associated with heart and cardiac muscle development and cardiovascular
phenotypes, consistent with the role of HOXA3 in the formation of the main arteries [23,27]
(Fig 1F). These observations are in line with HOX functional specificity and indicate that in
their physiological domains of expression, HOXA2 and HOXA3 bind in the vicinity of, and
potentially control, genes involved in very different processes. Hoxa2 expression displays a
sharp anterior border between BA1 and BA2 and expands in the more posterior PBA (Fig 1A,
Fig 4A). We profiled HOXA2 binding in PBA to understand if HOX-specific binding is deter-
mined by differences in the BA2 and PBA chromatin environment. We found that HOXA2
peaks in PBA very rarely overlap with HOXA3 ‘only’ peaks in the same tissue (1% overlap),
but are largely contained in the pool of HOXA2-specific binding in BA2 and ‘common’
HOXA2 and HOXA3 binding events (Fig 1H). This, combined with the observation that
Fig 1. HOXA2 and HOXA3 control diverse processes by targeting different regions of the genome in vivo. A. BA organization in mammals. BA3-6 are
collectively indicated as PBA. The same colour code (BA2 red, PBA green) is used throughout the manuscript. B. Heatmap of Hox expression in E10.5 mouse
BA1, BA2 and PBA, based on the normalized expression values count per million (CPM) [30]. C. Overlap of HOXA3 binding in PBA and HOXA2 binding in
BA2 (200 nt summits, overlap at least 1 nt). Only peaks with FE�10 are considered. D. UCSC tracks (mm9) of HOXA3 (green) and HOXA2 (red) specific and
shared peaks. E. Overlap (expressed as %) of increasing numbers of top HOXA2 and HOXA3 peaks (ranked by FE). High-confidence peaks show the smallest
overlap. FG. GREAT analysis of HOXA3- (F) and HOXA2- (G) specific peaks (non-overlapping, green and red bars respectively) shows association with genes
involved in different biological processes and whose mutations generate different phenotypes in mouse. The length of the bars corresponds to the binomial raw
(uncorrected) P-values (x-axis values). H. HOXA2 binding in PBA. Overlap of HOXA2 summit regions in PBA (FE�10, green) with HOXA2 summit regions
in the BA2 (red) and HOXA3 summit regions in the PBA (green); same rule as in C. HOXA2 binding locations are similar in BA2 and PBA.
https://doi.org/10.1371/journal.pgen.1009162.g001
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HOXA2 and HOXA3 are largely co-expressed in the same cells in PBA and therefore exposed
to the same chromatin environment [28] (see also Fig 4, S1A and S1B Fig) argues against dif-
ferences in chromatin accessibility being a main determinant of HOX binding. In sum, analy-
sis of HOXA2 and HOXA3 ChIP-seq in their respective domains of expression indicates that
different HOX TFs control diverse and specific processes by targeting different regions of the
genome in vivo. Tissue-specific chromatin accessibility does not appear to be a major determi-
nant in HOX paralogs’ target site selection.
HOXA2 and HOXA3 select variants of the HOX/PBX motif
The observations above indicate that HOXA2 and HOXA3 select different genomic sites in
vivo, while at a first glance, they recognize very similar DNA sequences. To investigate the
determinants of HOX binding specificity, we focused on high confidence HOXA2 and
HOXA3 peaks (top 250, ranked by FE), which display the lowest overlap across the genome
(Fig 1E). As expected, both HOXA2 and HOXA3 top peaks were enriched in the HOX/PBX
motif (present in 66.4% and 68.4% of HOXA2 and HOXA3 respectively). De novo motif dis-
covery identified enrichment of a HOX-PBX variant in HOXA3 top 250 peaks, which contains
a C in the second variable position (i.e. TGATNCAT) (Fig 2A). We next counted the distribu-
tion of all permutations of the TGATNNAT motif in top HOXA2 and HOXA3 peaks and
Fig 2. HOXA2 and HOXA3 select variants of the HOX/PBX motif. A. Homer detects different variants of the HOX-PBX motif in top 250 HOXA2
and HOXA3 peaks, with a G/C (HOXA3) or mainly a G (HOXA2) in the second variable position. B. Occurrence of HOX-PBX motif variants (all
permutations of the variable nucleotides in TGATNNAT) in top 250 HOXA2 and HOXA3 peaks (ordered into 50 region bins by decreasing FE). The
TGATTCAT motif (red arrows) is among the most enriched variants in HOXA3 peaks but does not virtually occur in HOXA2 peaks. C. Distribution
of differential H3K27 acetylation (PBA/BA2 ratio) at top 250 HOXA3 peaks containing the four most frequent TGATNNAT variants. Data is
ordered based on fold change of acetylation (fold change of normalized read counts) and divided into quartiles. The central quartiles (50% of the
data) are shown in the box, while top and bottom whiskers represent the top 25% and bottom 25% (the top and the bottom quartiles) of the data,
respectively. HOXA3 peaks containing the TGATTCAT variant are associated with increased enhancer activity in PBA (red line). D. UCSC tracks
with HOXA3, HOXA2, PBX and MEIS binding profiles in BA2 (red) and PBA (green) at the Sulf2 locus, containing TGATTCAT. No HOXA2
binding is detected in BA2 or PBA. E. Sequence of HOXA3 peak summit in D, corresponding to the probe used in F. The TGATTCAT motif
(underlined) is flanked by two MEIS motifs (also underlined); the C➔G substitution tested in G is indicated in red. F. HOXA3 can selectively bind
the Sulf2 probe in complex with PBX/MEIS. Incubation of the Sulf2 probe with TNT reticulocytes expressing HOXA2, HOXA3, MEIS/PBX,
HOXA2/MEIS/PBX or HOXA3/MEIS/PBX. MEIS/PBX bind the Sulf2 probe in combination (arrow). Addition of HOXA3 to the probe results in the
formation of a complex only in the presence of PBX/MEIS (arrow). No complex is formed when PBX/MEIS are co-translated with HOXA2. G. Same
experiment as in F, using a mutant Sulf2 probe (the nucleotide substitution is shown in E). HOXA2 can bind the mutant probe in combination with
MEIS/PBX (asterisk), similar to HOXA3 (arrow).
https://doi.org/10.1371/journal.pgen.1009162.g002
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found the TGATTCAT variant to be highly differentially enriched in HOXA3 peaks (Fig 2B).
This sequence, which is highly represented in HOXA3 top peaks (~ 20%), is almost excluded
from HOXA2 peaks (Fig 2B). Supporting functional significance, HOXA3 peaks containing
TGATTCAT display increased acetylation levels (a mark of active enhancers) [29] in HOX-
A3-expressing tissues (Fig 2C). In addition, while HOXA2 peaks display a very high represen-
tation of TGATGGAT and TGATTGAT, HOXA3 high confidence binding allows higher
variability (four variants are counted > 20 times in HOXA3 peaks as opposed to only two vari-
ants in top HOXA2 peaks) (Fig 2B). The highest differential enrichment of TGATNNAT vari-
ants is observed in top HOXA2 and HOXA3 peaks (S2A Fig), which also display minimal
overlap across the genome (Fig 1E); this suggests that the ability to recognize different
sequences plays a role in genomic site selections. Finally, the majority of HOXA3 (158/250)
and HOXA2 (160/250) top peaks contain MEIS recognition motif, at a preferential distance of
less than 20 nt from the TGATNNAT motif (S2B Fig). The Sulf2 locus exemplifies HOXA3
specific binding in PBA: HOXA3 peak summit contains a single TGATTCAT motif and dis-
plays high HOXA3 occupancy, but no detectable HOXA2 binding (Fig 2D and 2E). We used
electrophoretic mobility shift assay (EMSA) to establish if HOXA3 preferentially recognizes
the TGATTCAT sequence in vitro. We did not observe any HOXA2 or HOXA3 binding to the
Sulf2 probe (Fig 2F). Incubation with PBX and MEIS resulted in a probe shift. Addition of
HOXA3, but not HOXA2, resulted in the formation of a ternary complex, indicating that
HOXA3 can bind this site in combination with PBX and MEIS, while HOXA2 cannot (Fig
2F). In support of this conclusion, converting TGATTCAT to TGATTGAT (a single nucleo-
tide substitution in the Sulf2 probe), enables binding of HOXA2, in addition to HOXA3 (Fig
2G, S2C Fig). Finally, we observed no synergy between HOXA3, PBX and MEIS on the Sulf2
enhancer in transfection assays (S2D Fig), suggesting that additional TFs could function with
HOXA3 at this site; of note this HOXA3-specific site closely resembles AP-1 TF consensus
sequence [24]. These results indicate that HOXA3 and HOXA2 have diverse binding prefer-
ences and uncover the existence of sites that are exclusively recognized by HOXA3.
HOXA2 molecular control of BA2 identity
In contrast to HOXA3, which displays unique binding preferences for TGATTCAT, we did
not detect HOX-PBX variants exclusively recognized by HOXA2. To investigate the mecha-
nisms underlying HOXA2 control of BA2 identity, we examined HOXA2 binding events (top
peaks) in the vicinity of well-established HOXA2 downstream targets. Meis2 and Zfp703 are
associated with high levels of HOXA2 binding [18] (Fig 3A and S3A Fig) and are downregu-
lated in Hoxa2 null BA2 [26]. In addition, consistent with Meis2 and Zfp703 expression being
HOXA2-dependent, they are expressed at higher levels in BA2 than the HOX-less BA1 and the
HOXA3-positive PBA (Fig 3B) [18,30]. Meis2 and Zfp703 loci exhibit high HOXA2 and
HOXA3 binding in their vicinity, suggesting their associated chromatin is largely accessible in
both BA2 and PBA (Fig 3A and S3A Fig). The sequence contained in Meis2 peak is active in
the main domains of HOXA2 expression, the hindbrain and BAs in zebrafish (Fig 3C). When
tested in luciferase assays in NIH3T3 cells, the Meis2 functional enhancer displays higher activ-
ity in the presence of HOXA2, in combination with MEIS and PBX, relative to HOXA3 (Fig
3D). Meis2 enhancer activity is largely dependent on the integrity of its HOX-PBX site (Fig
3D). Adding TALE to the Zfp703 putative enhancer also significantly increased the difference
in HOXA2 and HOXA3 activation abilities (S3B Fig). However, adding HOXA2 and HOXA3
alone resulted in higher activation of the Zfp703 putative enhancer relative to Meis2 enhancer
(presumably due to the presence of a TAAT site within the HOX/PBX motif) and including
TALE did not significantly change HOXA2 activation. Similar to the Meis2 enhancer,
PLOS GENETICS HOX paralogs modify binding of TALE transcription factors at selected enhancers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009162 December 14, 2020 6 / 25
disruption of the HOX/PBX site significantly decreased luciferase activity (S3B and S3C Fig).
Finally, HOXD3, another representative of HOX paralog group 3, whose members have largely
overlapping functions in vivo [27], also displayed a lower activating capacity than HOXA2 on
Fig 3. HOXA2 control of target enhancers. A. UCSC tracks of HOXA2, HOXA3, PBX, MEIS binding and H3K27 acetylation profiles in BA2 (red)
and PBA (green) at the Meis2 locus. Strong HOX and TALE binding is observed in both tissues, with higher acetylation levels in BA2. B. Heatmap
shows Meis2 and Zfp703 expression in E11.5 mouse BA1, BA2 and PBA, based on the normalized expression values CPM [30]. C. Meis2 enhancer is
active in the hindbrain (h) and the BAs (ba, arrow) of developing zebrafish (72 hours post fertilization), which correspond to Meis2 expression
domains in mouse [18]. The enhancer sequence spans the 200nt summit of HOXA2 peak in A. D. Luciferase activity driven by Meis2 enhancer co-
transfected with Hoxa2 (red bar) or Hoxa3 (green bar) in combination with Meis2 and Pbx1a expression vectors in NIH3T3 cells. The combination of
Hoxa2 with Meis2 and Pbx1a results in the highest activation. Changing the HOX-PBX site (empty bars, mutant sequence in F) reduces HOX-TALE
activation. E. Luciferase activity driven by Meis2 enhancer co-transfected with Hoxa2-a3HD (red empty bar) or Hoxa3-a2HD (green empty bar) and
Meis2 and Pbx1a. Values shown in DE represent fold activation over basal enhancer activity and are presented as the average of at least two
independent experiments, each performed in triplicate. Error bars represent the standard error of the mean (SEM). One-way ANOVA with post-hoc
Tukey HSD (Honestly Significant Difference) test: �� = p<0.005; ��� = p<0.0005. F-G. Incubation of the Meis2 probe with TNT reticulocyte
expressing HOXA2, HOXA3, MEIS/PBX, HOXA2/MEIS/PBX or HOXA3/MEIS/PBX as indicated. F. MEIS and PBX bind the Meis2 probe together
(black arrow, see also S3E and S3F Fig). Addition of HOXA2 and HOXA3 results in a trimeric protein complex (red and green arrows respectively).
Co-translation of HOXA2 with PBX/MEIS gives rise to a stronger trimeric complex relative to HOXA3 and, accordingly, to a decrease in PBX-MEIS
binding as a dimer (black arrow; see also S3G Fig for quantification). G. HOX binding to Meis2 probe, alone and in combination. The total HOX dose
is unvaried and corresponds to 100%; HOXA2 and HOXA3 are translated alone and co-translated with each other at different ratios, as follows: 100%
HOXA2; 75% HOXA2 + 25% HOXA3; 50% HOXA2 + 50% HOXA3; 25% HOXA2 + 75% HOXA3; 100% HOXA3. Colour coded % are indicated
below the gel; HOXA2 is red and HOXA3 is green. HOXA2 forms a stronger trimeric complex (red arrow) than HOXA3 (green arrow) at comparable
concentrations. PBX/MEIS dimeric complex, black arrow (see also S3H and S3I Fig for quantification). H. Swapping HOXA3-HD with HOXA2-HD
does not improve the ability of HOXA3 to form a ternary complex with PBX and MEIS (green arrows), and does not decrease HOXA2 binding with
MEIS and PBX (red arrows). Adding HOXA2 (or HOXA2-A3HD) results in higher intensity of the trimeric complex (red arrows) and lower intensity
of TALE dimeric complex relative to HOXA3 (or HOXA3-A2HD), as observed in F. I. Quantification of MEIS/PBX binding to Meis2 mutant probes.
The sequence of Meis2 wild-type and mutant probes is shown below: HOX-PBX and MEIS motifs are underlined and nucleotide substitutions are
shown in red. Mutants are as follows: m1 and m2 contain mutations in each half of the HOX-PBX site, m1+m2 in both halves; m3 contains mutations
in MEIS site closest to HOX-PBX motif and m4 bears mutations in both MEIS sites. MEIS/PBX binding to each mutant probe is expressed as relative
percentage to PBX/MEIS binding to Meis2 wild-type in the absence of HOX. Binding of PBX/MEIS dimer was quantified in the absence (black boxes)
and in the presence of HOXA2 (red boxes) and HOXA3 (green boxes). Values are the result of three independent experiments; for accurate
quantification, each gel was run with the reference condition (PBX/MEIS bound to Meis2 wild-type in the absence of HOX). All mutations
significantly decrease PBX/MEIS binding (p<0.0005, one-way ANOVA with post-hoc Tukey HSD test). J. Top HOXA2 and HOXA3 overlapping
peaks (total of 60/250 intersecting HOXA2 and HOXA3 top peaks) are more frequently associated with genes with higher expression in BA2 (red)
relative to PBA (green). The white portion of the pie chart refers to genes that are not differentially expressed between BA2 and PBA (no DE). Gene
association is based on GREAT standard association rules; expression levels are extracted from E11.5 RNA-seq [30].
https://doi.org/10.1371/journal.pgen.1009162.g003
PLOS GENETICS HOX paralogs modify binding of TALE transcription factors at selected enhancers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009162 December 14, 2020 7 / 25
Meis2 enhancer (S3D Fig). In sum, HOXA2 is more efficient at activating both target regions,
in the presence of PBX and MEIS. To understand if this reflects HOXA2 and HOXA3 different
DNA binding properties, we generated HOX chimeric proteins by swapping HOXA2 and
HOXA3 DNA-binding HDs. We found that providing HOXA2 with HOXA3 HD did not sub-
stantially change the ability of HOXA2 to activate transcription from the Meis2 enhancer (Fig
3E). Similarly, the ability of HOXA3 to transactivate the Meis2 and Zfp703 enhancers, alone or
in complex with MEIS and PBX, was not improved by swapping HOXA3 HD with HOXA2
HD (Fig 3E and S3B Fig). As HOX TFs cooperate with MEIS and PBX to activate target
enhancers and activation relies on the presence of an intact HOX/PBX recognition motif,
HOXA2 and HOXA3 diverse activation properties may depend on their respective abilities to
interact with PBX and MEIS on DNA. On their own, HOXA2 and HOXA3 weakly bind the
Fig 4. AB. In situ hybridization on E9.5 embryos, using Hoxa2 (A) and Hoxa3 (B) probes. A. Hoxa2 is highly expressed in the neural crest migrating
from rhombomere 4 (asterisk) to the BA2 (arrow). The portion of neural crest migrating just below the otic vesicle (OV) into the BA3 (arrowhead) is also
Hoxa2-positive. B. Hoxa3 is expressed in the BA3 (arrowhead). C. Distribution of HOXA2 peaks FE in BA2 and PBA. HOXA2 peaks in BA2 and PBA
are ordered based on log2 FE and divided into quartiles. The central quartiles (50% of the data) are shown in the box, while top and bottom whiskers
represent the top 25% and bottom 25% (the top and the bottom quartiles) of the data, respectively. HOXA2 peaks display a significantly higher FE in
BA2 compared to PBA (p< 2.2e-16; one sided Welsh two sample t-test). D. Comparison of HOXA2 binding in BA2 (red bars) and PBA (green bars) by
ChIP-qPCR. Enrichment of each region following immunoprecipitation with HOXA2 and IgG negative control antibody (Neg Ab) is calculated as
percentage input; numbers indicate the corresponding FE values in HOXA2 ChIP-seq (BA2 and PBA). Peaks are labelled by their closest genes. Itih4 is a
negative control (unbound region). Values represent the average of duplicate samples, and error bars indicate the SEM. E. HOX binding to Meis2 probe,
alone and in combination. Co-translation of HOXA2 with PBX/MEIS and with or without HOXA3; the same applies to HOXA3. The highest HOX dose
corresponds to 100%; HOXA2 (red) is translated at progressively decreasing levels, either alone, or co-translated with progressively increasing levels of
HOXA3 (green) (e.g. 75% HOXA2; 75% HOXA2 + 25% HOXA3; 50% HOXA2; 50%HOXA2 + 50% HOXA3; 50% HOXA3 as indicated below the gel).
At 50% and 25% levels, HOXA2 forms a significantly stronger trimeric complex (red arrow) on its own than when HOXA3 is added. PBX/MEIS dimeric
complex, black arrow; HOXA3/PBX/MEIS trimeric, green arrow (see also S4C Fig). F. Luciferase activity driven by Meis2 and Zfp703 enhancers co-
transfected with expression vector for Hoxa2 or Hoxa3, alone, or at diverse ratio of Hoxa2 to Hoxa3 (3:1; 2:2; 1:3) as indicated. All samples contain Meis2
and Pbx1a expression vectors; Hoxa2 and Hoxa3 are added as indicated. For both enhancers, luciferase activity decreases as Hoxa2 is progressively
replaced by Hoxa3 (asterisks indicate significant difference relative to full dose of Hoxa2); for Meis2, enhancer activation is significantly higher with half
dose of Hoxa2 alone, relative to Hoxa2 and Hoxa3 together. Values represent fold activation over basal enhancer activity and are presented as the average
of at least two independent experiments, each performed in triplicate. Error bars represent the SEM. One-way ANOVA with post-hoc Tukey HSD test: �
= p<0.01; �� = p<0.001.
https://doi.org/10.1371/journal.pgen.1009162.g004
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Meis2 enhancer, but interact with PBX and MEIS to form a ternary protein complex on DNA
(Fig 3F, see also S3E and S3F Fig). A larger fraction of MEIS-PBX complex is bound by
HOXA2, while addition of HOXA3 results in a less robust super-shift of the dimeric band (Fig
3F and S3G Fig). To confirm these observations, we co-translated HOXA2 and HOXA3 at dif-
ferent ratios and found that, at all concentrations tested, HOXA2 forms a stronger trimeric
complex on the Meis2 probe, relative to HOXA3 at an equivalent concentration (Fig 3G and
S3H Fig). Concomitantly, HOXA2 shifts more of the dimeric band (PBX/MEIS) into a tri-
meric complex (Fig 3G and S3I Fig). We did not detect any slower complexes, suggesting that
this DNA sequence can only bind HOXA2 or HOXA3 at one time (Fig 3G and S3J Fig). We
observed the same binding patterns using HOX chimeras: swapping HOXA3-HD with HOX-
A2-HD did not improve the ability of HOXA3 to form a ternary complex with PBX and MEIS,
and did not affect HOXA2 ability to bind DNA in complex with MEIS and PBX (Fig 3H, S3G
Fig). Next, we investigated the contribution of HOX-PBX and MEIS recognition motifs to
HOX and TALE binding to DNA. We systematically introduced mutations in individual sites
and tested the resulting probes in EMSA. All mutations strongly reduced the formation of
PBX-MEIS dimers (Fig 3I and S3K Fig). We only detected formation of HOX-MEIS-PBX tri-
meric complexes when one of the two MEIS recognition motifs was still intact, and even in
this case complex formation was strongly decreased (S3K Fig), highlighting an essential role of
MEIS for HOX binding to DNA. Together, these results indicate that the differential ability of
HOXA2 and HOXA3 to bind DNA and activate transcription does not depend on HOX-DNA
binary binding. Rather, it reflects differential abilities to form functional HOX-TALE com-
plexes on DNA and is encoded by residues outside the HOXA2 and HOXA3 HD. In summary,
while HOXA2 does not exclusively access its sites (HOXA3 can bind as well, Fig 3A), HOXA2
binds more efficiently with TALE at these sites, leading to increased transcriptional activation.
Consistently, shared high-confidence HOXA2 and HOXA3 binding events are largely associ-
ated with genes expressed at higher levels in the BA2 (Fig 3J). Thus, at least in part, HOXA2
instructs the formation of a BA2 by raising the expression levels of HOX-regulated genes. Cru-
cially, among these genes is Meis2, which encodes a critical component for BA2 identity [18].
HOXA2 activity is decreased in PBA
The above results show that, on its target enhancers, HOXA2 functions more efficiently with
TALE relative to HOXA3. Given that HOXA2 is expressed in both the BA2 and in the PBA,
why does HOXA2 not instruct a BA2-specific program in the PBA as well? More posterior
Hox genes are typically able to repress the expression (and suppress the function) of more
anterior genes, a process termed ‘posterior prevalence’ [15]. Indeed, Hoxa2 highest expression
is detected in the BA2, while Hoxa2 is expressed at lower levels in Hoxa3 main domain of
expression, the BA3 (Fig 4A and 4B and Fig 1B). A lower nuclear concentration of HOXA2 is
expected to reduce HOXA2 binding to DNA (Fig 3G and S3H Fig). However, to assess how
changes in HOXA2 dose affect binding genome-wide, we compared HOXA2 binding in BA2
and in PBA. While HOXA2 binds similar locations in BA2 and PBA (Fig 1H), HOXA2 bind-
ing levels are significantly higher in BA2 (Fig 4C, see also S3A Fig). This is further confirmed
by quantitative analysis of selected immunoprecipitated regions (Fig 4D). Relative to the BA2,
the PBA display lower levels of HOXA2 and also express HOXA3 (Fig 1B). Indeed single cell
analysis of E10.5 post-otic cranial neural crest, which includes the PBA, [28] (S4A and S4B
Fig) confirms that HOXA2 and HOXA3 are largely expressed in the same cells. Therefore, we
investigated the effect of decreasing HOXA2 levels while increasing HOXA3 levels on HOXA2
target enhancers. Using EMSA, we found that at lower HOXA2 levels, the addition of HOXA3
significantly reduced binding of HOXA2 to the Meis2 probe, together with PBX/MEIS (Fig 4E,
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S4C Fig). Similarly co-expressing HOXA2 and HOXA3 in NIH3T3 cells reduced activation of
HOXA2 target enhancers in vitro (Fig 4F); for Meis2, halving the amount of HOXA2 (50%
HOXA2) resulted in higher activation compared to doubling the levels of HOX proteins (50%
HOXA2 + 50% HOXA3). While these observations are entirely consistent with the observed
lower levels of HOXA2 targets in PBA (Meis2, Zfp703), it is unknown if expression of these
genes in the PBA is still dependent on HOXA2 or HOX paralog 3. Provided expression of
Meis2, Zfp703 is required for correct PBA development, as this area does not display any phe-
notype in the absence of HOXA2 [21,22], either HOXA2 is not required for their expression,
or its function can be fully compensated by HOX paralog 3. In conclusion, both a lower dose
of HOXA2 and the presence of HOXA3 (possibly other paralog 3 as well) decrease HOXA2
binding and activating abilities in the PBA. This effect, combined with the lower efficiency of
HOXA3 to activate HOXA2 targets, dampens HOXA2 transcriptional program in the PBA.
HOX cooperates with MEIS
Our results indicate that HOX selectivity is displayed in concert with TALE. Generally, bind-
ing with TALE appears to be a dominant feature of HOX binding in the BAs. HOX peaks are
enriched in HOX-PBX and MEIS motifs and similar to HOXA2 in BA2 [18], HOXA3 peaks
overlap almost entirely with MEIS and PBX peaks in the same embryonic tissue at the same
stage (Fig 5A, S5A Fig). We previously discovered that HOXA2 switches its transcriptional
program by increasing binding of MEIS TFs to potentially lower-affinity sites across the
genome [18]. We investigated if HOXA3 can similarly increase MEIS binding levels. The frac-
tion of MEIS peaks that overlaps HOXA3 binding displays higher FE in PBA, relative to the
HOX-free BA1 (Fig 5B). Hoxa2 is also expressed in PBA, where it could be entirely responsible
for the observed increase in MEIS binding. Therefore, to assess HOXA3 unique contribution
to MEIS binding increase, we extracted HOXA3-specific binding. We found that MEIS peaks
in PBA that overlap HOXA3 ‘exclusive’ peaks, display higher FE (relative to MEIS non-over-
lapping HOX), indicating that HOXA3 also increases binding of MEIS (Fig 5C), similar to
HOXA2 in BA2 [18]. Reciprocally, co-occupancy with MEIS enhances HOXA3 binding (Fig
5D). Both HOXA2 and HOXA3 interact with MEIS1 and MEIS2 in co-precipitation experi-
ments (Fig 5E). Cooperativity, an inherent feature of TF binding to DNA, can arise by protein-
protein interactions (direct cooperativity) or by collective binding of TFs to nearby sequences
and nucleosome displacement (indirect cooperativity) [31]. The observations that HOX and
MEIS display higher binding levels, when binding chromatin together, and interact to form a
complex, identify direct cooperativity as the mechanism underlying HOX-TALE binding to
chromatin. Cooperativity with MEIS appears to be a general operational principle of HOX TFs
as, similar to HOXA2 and HOXA3, MEIS co-occupancy with HOXA1 and HOXA9 is associ-
ated with the highest MEIS binding levels in mouse embryonic stem cells [32] and bone mar-
row cells [33] respectively (S5B–S5D Fig). In sum, HOX directly cooperate with TALE on
chromatin. HOXA2 and HOXA3 diverse sequence preferences and binding affinities predict
that HOX paralogs preferentially cooperate with distinct subsets of TALE binding events.
MEIS ‘ubiquitous’ binding is converted into tissue-specific enhancer
activity
MEIS TFs bind broadly and to largely overlapping locations across different BAs (Fig 6A). In
contrast to MEIS ubiquitous occupancy, MEIS binding levels are BA-specific (Fig 6B and 6C)
and are associated with distinct biological processes (S6A Fig). We systematically extracted
MEIS differential binding across the BAs (S7 Fig) and found that higher MEIS binding levels
in a tissue are highly predictive of increased enhancer activity in the same tissue (Fig 6D).
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Moreover, consistent with MEIS positive effects on transcription [34], genes preferentially
expressed in one tissue display higher MEIS binding levels in their vicinity, in a pattern mir-
roring changes in H3K27Ac across the BAs (Fig 6E). As high MEIS binding levels are tissue-
specific and linked to transcriptional activation, we next asked what causes differences in
MEIS binding levels across the BAs. Consistent with the finding that HOXA2 enhances MEIS
occupancy at selected sites across the genome to activate gene expression [18], regions occu-
pied by HOXA2 in BA2, and by HOXA3 in PBA, display higher enhancer activity if associated
with higher, differential MEIS binding levels in the corresponding tissue (Fig 6F). Likewise
high MEIS peaks in HOX-positive areas (BA2 and PBA) are highly enriched in sequence fea-
tures matching HOX-PBX motif [35]. However, HOX co-occupancy only partly accounts for
high levels of MEIS binding and acetylation in BA2 and PBAs (S6B Fig), suggesting additional
TFs may be involved. TF occupancy in vivo occurs in the context of chromatin, which acts as a
barrier to TF binding. Multiple TFs that recognize closely spaced binding sites can more effec-
tively compete with nucleosomes and indirectly facilitate each other’s binding. We reasoned
that this indirect form of cooperativity between TFs could enhance MEIS binding, resulting in
Fig 5. HOX cooperate with MEIS. A. Overlap of HOXA3 with MEIS and PBX peaks in the same tissue (PBA) and at the same
embryonic stage (E11.5) (200nt summit regions, overlap at least 1nt). The proportional Venn diagram is cropped to focus on
HOXA3 peaks. B. Barplots of fold change in MEIS binding levels in PBA versus BA1. Regions co-occupied by MEIS with
HOXA3 in PBA generally display higher MEIS binding levels in PBA (HOX-positive) relative to the HOX-negative BA1. In
contrast, MEIS binding not overlapping HOXA3 can be higher in BA1 or in PBA. Fold changes in MEIS peaks were calculated
using EdgeR (see also S7 Fig). C. Distribution of FE across different groups of MEIS peaks (PBA). MEIS peaks are sorted into:
peaks not overlapping HOX (light green), MEIS peaks overlapping HOXA3 only (‘exclusive’ peaks, i.e. not overlapping HOXA2
in PBA, darker green) and MEIS peaks overlapping HOXA2 and HOXA3 (darkest green). Kernel density plot shows that MEIS
peaks overlapping HOX display higher FE relative to MEIS only peaks. D. Distance of HOXA3 peaks relative to MEIS peaks
(PBA). HOXA3 peaks are binned according to their log10 distance to the nearest MEIS peak and labelled according to FE (high
FE, dark red bars; low FE, dark blue bars). High HOXA3 peaks mainly occur within 1kb of a MEIS peak. E. Co-precipitation
assays. HEK293 cells were co-transfected with expression vectors for FLAG-tagged HOXA2 or HOXA3 and GST-tagged MEIS1,
GST-tagged MEIS2 or GST alone. Protein interactions were assayed by co-precipitation on glutathione beads directed toward the
GST tag and eluted proteins analysed by western blotting to detect the presence of FLAG-HOXA2 or FLAG-HOXA3 (red box,
Co-P). Cell lysates were analysed by western blotting prior to co-precipitation to detect protein expression (input).
https://doi.org/10.1371/journal.pgen.1009162.g005
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Fig 6. A. Proportional Venn diagram shows highly overlapping binding of MEIS in BA1, BA2 and PBA. MEIS peaks were combined and re-centered using
DiffBind; out of 215830 MEIS peaks, 101055 are in common between the three tissues. B. Top MEIS peaks are different in BA2 and PBA. At high FE, there is a
lower overlap between MEIS binding in BA2 and PBA. The ratio of MEIS peaks, which are common to BA2 and PBA, increases as FE decreases. C. UCSC tracks
illustrate the different MEIS binding levels in BA1-BA2-PBA at the Zfp496 and Zfpm1 loci. Instances of common MEIS peaks higher in one tissue (PBA) are
shaded. D. Correlation plot of differential MEIS binding and differential acetylation (enhancer activity) at intergenic regions (PBA versus BA2). Each point
corresponds to a region with MEIS log2 fold change>1 (FC>2); the corresponding H3K27ac value is plotted. Changes in MEIS binding levels are positively
correlated with increased enhancer activity in the same tissue (correlation = 0.73). E. Boxplots of MEIS binding and H3K27Ac levels (log2 fold change) associated
with differentially expressed genes. Peaks are associated with intragenic and intergenic (+/-100kb from transcription start and end sites) regions of differentially
expressed genes (higher expression in PBA, green; higher expression in BA2, red; non-differentially expressed, grey). Irrespective of location, MEIS binding and
acetylation levels are significantly higher (p<2.2e-16, one-sided t-test) when associated with genes with higher expression in the same tissue, relative to MEIS
binding and acetylation associated with genes expressed at the same levels in BA2 and PBA. Data is ordered based on fold change of acetylation and MEIS
binding (fold change of normalized read counts) and divided into quartiles. The central quartiles (50% of the data) are shown in the box, while top and bottom
whiskers represent the top 25% and bottom 25% of the data, respectively. F. Changes in H3K27ac (log2RPKM) in BA2 and PBA for all HOX peaks and for HOX
peaks overlapping MEIS differential binding higher in BA2 (HOXA2 peaks) and higher in PBA (HOXA3 peaks). Data is ordered based on fold change of
acetylation (fold change of normalized read counts), as described above. HOX binding generally increases H3K27Ac; peaks associated with increased MEIS
binding display a significantly higher increment of H3K27Ac in the same tissue (One-way ANOVA with post-hoc Tukey HSD; �� = p<0.001). G. CNN models of
MEIS differential peaks uncover enrichment of tissue-specific sequence motifs as described [35]. MEIS binding was classified in six categories (i.e. peaks with
higher/lower binding in BA1, BA2, PBA). CNN analysis identifies tissue-specific sequence features in each class of MEIS peaks. Predicted GATA binding in a
MEIS PBA up-binding region is visualised as in the example (a feature matching GATA TF recognition motif on chr5:104257972-104258015 is shown). GATA6
ChIP-seq in PBA verifies this prediction. HOMER was used to cluster and annotate tissue-specific sequence features; features enriched in the different classes of
MEIS peaks are matched to TF families with known tissue-specificity (see also Fig 6H). H. Heatmap of the expression of selected TF families, corresponding to
cognate recognition motifs identified in MEIS PBA-up, in E11.5 mouse BA2 and PBA. Members of the GATA and TBX families, and the majority of expressed
Forkhead TFs are enriched in PBA relative to BA2. Only TFs with expression values> 10 cpm in at least one tissue are shown. I. HOMER de novo motif
discovery in HOXA3-specific and HOXA2-specific peaks. HOXA3-specific are HOXA3 peaks excluding peaks overlapping with HOXA2 BA2; similarly,
HOXA2-specific are HOXA2 peaks excluding peaks overlapping with HOXA3 PBA. HOMER identifies enrichment of the same motifs enriched in BA-specific
MEIS differential binding, Forkhead motif in HOXA3-specific (shaded in green) and BHLH motif in HOXA2-specific subsets (shaded in red). Variations of HD
recognition motifs potentially recognized by HOX and attributed by HOMER to PBA-specific TFs NKX and ISL1 in PBA and LHX/DLX in BA2 are also
enriched. J. Effects of Forkhead and GATA motifs on HOX and MEIS binding, assessed by in silico knockout. CNN MEIS PBA ‘up-binding’ features (Fig 6G)
were annotated as HOX, GATA, and Forkhead (see methods). Co-occurring HOX- Forkhead motifs (distance between 1 nt to 100 nt) were selected for in silico
mutagenesis. Forkhead mutagenesis results in a significant drop in HOXA3 binding in PBA, but shows no average significant effect on HOXA2 in BA2.
Similarly, Forkhead mutagenesis significantly decreases Meis PBA binding across most tested sites. In comparison, much weaker effects are predicted on BA1
and BA2 MEIS differential binding. As a negative control, the same procedure was applied to co-occurring HOX-GATA motifs. GATA motif mutagenesis does
not show significant average effects on HOX, or MEIS in HOX-bound regions. K. Luciferase activity driven by Sfrp2 enhancer co-transfected with Meis alone
(grey bar) and with Hoxa2 (red empty bars), Hoxa3 (green empty bars); Meis and Pbx with Hoxa2 (red bars) and Hoxa3 (green bars) in the absence (left half of
the graph) and in the presence of Foxc1 (right half of the graph, as indicated) in NIH3T3 cells. The last two samples contain Sfrp2 enhancer co-transfected with
Hoxa2 (red empty bars), Hoxa3 (green empty bars). Adding Foxc1 to Hoxa2 or Hoxa3 with Meis2 and Pbx1a results in the highest activation.
https://doi.org/10.1371/journal.pgen.1009162.g006
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higher MEIS peaks. Therefore, to identify BA-specific TFs that facilitate MEIS binding, we
searched for enriched sequence features in MEIS differential binding. CNN models identify
enrichment of distinct signature motifs in MEIS differential peaks (Fig 6G), which reflect the
distribution of TFs across the BAs (Fig 6H). In support of tissue-specific TFs contributing to
MEIS binding levels, GATA6 occupancy in the PBA [30] overlays MEIS peaks, higher in the
same tissue (S6C Fig). These observations suggest that binding of tissue-specific TFs, in addi-
tion to HOX, can locally increase MEIS binding levels.
We noticed that a set of distinctive sequence features of MEIS differential binding in PBA
[NKX (HD) and FOX (Forkhead) motifs] and BA2 [(basic helix-loop-helix (bHLH) recogni-
tion sites] (Fig 6I) are also enriched in HOXA3- and HOXA2-specific peaks, respectively, sug-
gesting that HOX and tissue-specific TFs may collaborate in binding with TALE. We decided
to focus on FOX TFs, as most Fox genes are expressed at higher levels in PBA than BA2 (Fig
6H). Consistent with the three factors cooperating on chromatin, HOX and FOX recognition
sites co-occur in the same differential MEIS peaks (S6D and S6E Fig). The higher levels of
FOX TFs in the PBA, relative to BA2, predict FOX TFs to have stronger effects on HOXA3
and MEIS binding in PBA. CNN can be trained to predict binding intensities merely based on
DNA nucleotide sequence, and the learned model can be used to predict changes in binding
intensities upon random dinucleotides mutations in TF binding motifs (in silico mutagenesis).
Indeed, in silico mutagenesis predicts mutations in FOX TF recognition sites to affect binding
of both HOXA3 and MEIS in PBA, but not HOXA2 and MEIS in BA2 (Fig 6J, S6F Fig). In
contrast, mutagenesis of GATA motifs (enriched in MEIS differential peaks, but not in HOX
peaks) does not appear to affect HOX-MEIS binding (Fig 6J). Synergistic effects of FOX and
HOX have been identified in the mouse central nervous system [36]. In luciferase assays, addi-
tion of FOXC1, HOX and MEIS/PBX increases transcriptional activation driven by the Sfrp2
distal region (co-occupied by HOX and FOXC1 in the BAs) [18] (Fig 6K). While naked DNA
in transfection assays does not recapitulate TF cooperativity on chromatin, these results imply
that TALE FOX and HOX TFs bind their predicted binding sites and together, contribute to
transcriptional activation. Moreover, the presence of FOXC1 is sufficient to enhance MEIS/
HOX transcriptional activation of Sfrp2 enhancer, suggesting that cooperation between these
TFs could partly compensate for lack of PBX (Fig 6K).
These results identify (direct or indirect) cooperativity with tissue-specific TFs as an addi-
tional mechanism for HOX selectivity. By enhancing MEIS binding (residence time on chro-
matin), tissue-specific TFs also contribute to promote the stability of HOX-MEIS complexes in
specific tissues. The distribution of tissue-specific motifs in HOX peaks suggests this mecha-
nism accounts for HOX selectivity at a subset of enhancers, rather than being a general mecha-
nism of HOX enhancer selection (S6G Fig). We propose that HOX and tissue-specific TFs
(alone and in combination) increase TALE TF binding affinity and residence time at selected
locations, identified using their sequence recognition motifs. As high levels of MEIS are associ-
ated with increased enhancer activity and gene expression, longer MEIS residence time at
selected locations may translate into BA-specific transcriptional outputs.
Discussion
HOX TFs contain a HD, which display highly similar sequence recognition properties and is
shared by hundreds of TFs, yet they instruct diverse, segment-specific transcriptional pro-
grams along the antero-posterior axis of all bilaterian animals. By profiling HOXA2 and
HOXA3 binding in their physiological domains, we identify three main determinants of
HOX-selective binding across the genome: 1) recognition of unique variants of the HOX-PBX
motif; 2) differential affinity at ‘shared’ HOX-PBX motifs and; 3) presence of additional tissue-
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specific, non-TALE, TFs. These mechanisms (with the possible exception of the first) are
expected to generate quantitative (rather than qualitative, i.e. binding/no binding) differences
in the relative levels of HOX/TALE occupancy on commonly bound regions. Such quantitative
changes are a feature of continuous networks [37], in which TFs bind a continuum of func-
tional and non-functional sites and regulatory specificities derive from quantitative differences
in DNA occupancy patterns.
HOX paralog-selective binding occurs in cooperation with TALE. The high degree of HOX
and TALE interaction flexibility, mediated by paralog-specific protein signatures, has been
proposed to generate paralog-specific functions of HOX TFs [38]. Here, by defining the in vivo
repertoire of HOX occupied sites, we identify DNA sequence as an additional determinant of
HOX-TALE functional specificity in vivo. This finding is consistent with the mechanism of
latent specificity described for Drosophila Hox/Exd (PBX) interaction [39] and in vitro obser-
vations that HOX TFs bind longer, more specific sequence motifs in the presence of TALE.
However, the effects of TALE on HOX binding in vivo go beyond the refinement of HOX
binding sites as, at least in the BA context, binding with TALE appears to be a requirement for
loading HOX on chromatin. Our observations indicate that HOXA2-A3 overwhelmingly rec-
ognize genomic sites that are enriched in HOX-PBX motifs and are also occupied by TALE
TFs in vivo. Therefore, TALE provides a platform for HOX to bind; selectivity enables HOX
paralogs to preferentially bind different subsets of this common platform. In agreement with
our finding that BA-specific chromatin states do not seem to play a role in HOX target site
selection, TALE platform is largely similar across BA1-2-PBA.
What is the functional significance of HOX-TALE interaction on chromatin and how does
it contribute to paralog-specific transcriptional programs? Many examples from animal devel-
opment indicate that transcriptional regulation is mediated by distinct combinations of TFs.
TALE TFs operate as a hub, which assists combinatorial assembly of TF complexes. TALE plat-
form enables HOX function to be modulated by other TFs; in doing so, it integrates positional
signals (encoded by HOX) and local inputs (provided by cell type-/tissue-specific TFs) into
defined transcriptional outputs. While it is possible that MEIS and PBX facilitate access of
diverse TFs to relatively inaccessible chromatin, MEIS TFs differ from conventional pioneer
TFs, which function to open chromatin regions but are not directly involved in enhancer acti-
vation [40,41]. Remarkably, independently of the type of TF involved (HOX or other tissue-
specific TFs), positive changes in MEIS binding result in a functional effect, i.e. increased
enhancer activity. High instances of MEIS binding are typically tissue-specific and highly cor-
related with enhancer activity. In fact, differential MEIS binding in a specific BAs is generally a
very good predictor for matching changes in enhancer activity in the same tissue. Based on
our observations and the well-established role of MEIS in transcriptional activation [34,42,43],
we propose a model of transcriptional activation, where TALE (MEIS) TFs function as broad
or general activators and HOX paralog selectivity is mainly directed at harnessing TALE func-
tional activity at selected locations. Using their recognition motifs, HOX and/or tissue-specific
TFs select specific MEIS binding locations, where they stabilize MEIS binding to generate pre-
cise functional outputs, or patterns of enhancer activation (Fig 7). Interestingly, MEIS2 inter-
acts with PARP1 [43], a large enzyme capable of triggering phase condensation [44].
Increasing MEIS residence time (as a result of the cooperation with HOX and other TFs) may
favour PARP1 recruitment at selected loci and, in turn, generate the liquid-liquid phase transi-
tions observed to promote gene activation [8,45].
Because high instances of MEIS binding are typically associated with combinatorial TF
binding, a precise identification of the critical steps for enhancer activation, and their sequen-
tial order, remains problematic. For similar reasons, MEIS and PBX shared genomic occu-
pancy complicates dissecting their respective contributions to enhancer binding and
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activation. In addition to TALE, numerous other TFs are broadly, if not ubiquitously expressed
during development, yet their inactivation results in tissue-specific phenotypes. It is tempting
to speculate that similar principles of TF functional connectivity could explain other transcrip-
tional networks, i.e. that cell type- tissue-specific regulators harness the activation abilities of
broadly expressed TFs to generate cell type -specific gene expression programs.
Material and methods
Ethics statement
Experiments using animals were performed in accordance with legislation in the UK Animals
(Scientific Procedures) Act of 1986 (PPL 70/8858 to Graham Morrissey). All procedures on
zebrafish adults and embryos were approved by the University of Massachusetts Institutional
Animal Care and Use Committee (IACUC).
Animal experiments
CD1 mice were time-mated to obtain BA2 or PBA from E115 embryos. Mouse experiments
were carried out under ASPA 1986. Wild type zebrafish were raised in the University of Massa-
chusetts Medical Center Zebrafish Facility. Embryos and adult zebrafish were maintained
under standard laboratory conditions. Enhancers were amplified from mouse genomic DNA
using the primers (listed in S3 Table), cloned into pCR8/GW/TOPO vector (Life Technolo-
gies) and recombined using the Gateway system (Life Technologies) to an enhancer test vector
that includes a strong midbrain enhancer (Minitol2-GwB-zgata2-GFP-48, a kind gift from JL
Skarmeta) as an internal control. Fertilized zebrafish embryos were collected from natural
spawnings. Plasmid DNA was injected into the cytoplasm of one-cell stage embryos. Injected
Fig 7. Model. Low affinity, widespread binding of MEIS (blue square) defines a large subset of accessible chromatin (grey
line) for activation (PBX is not shown as PBX and MEIS binding almost entirely overlap). Direct cooperativity with HOX
(A2 and A3, red and green circles respectively) and/or indirect cooperativity with tissue-specific TFs (triangle) increase
MEIS binding affinity and residence time; prolonged residence time of MEIS at enhancers promotes recruitment of general
co-activators (yellow) and activation of transcription. HOX paralogs preferentially bind different subsets of MEIS occupied
regions, resulting in differential transcription. Three examples of BA-specific transcription are shown. In a, the red site is
bound with higher affinity by HOXA2 than HOXA3, resulting in the formation of a more stable HOX-TALE complex on
DNA and a (higher) transcriptional output in BA2. Conversely, in c, the green site is only recognized by HOXA3, leading to
high affinity MEIS binding only in PBA, and to PBA-specific transcription. In b, the effect of HOXA3 is potentiated by a
PBA-specific TF binding in the vicinity. Co-binding with tissue-specific TFs may positively contribute to HOX-MEIS
cooperativity by competing with nucleosome for DNA binding, especially at HOX and/or MEIS low affinity sites. These
mechanisms result in BA-specific transcription.
https://doi.org/10.1371/journal.pgen.1009162.g007
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embryos were visualized intermittently by fluorescence microscopy up to 48 hr post fertiliza-
tion to identify transgenic carriers. These were raised to adulthood, outcrossed to wildtype fish
and the resulting F1 embryos were scored for GFP expression in order to generate stable trans-
genic lines.
Next-generation sequencing data and downstream analyses
ChIP-seq was performed as described [30] using rabbit polyclonal antibodies targeting
HOXA3 (non-conserved N-terminal amino acids 24 to 180), HOXA2 [46], PBX1-2-3-4 (sc-
25411X, Santa Cruz), MEIS1/2 (sc-10599X, Santa Cruz) and rabbit IgG (Millipore). DNA was
recovered from two independent ChIP-seq experiments and purified using DiaPure columns
(Diagenode). Enrichment was validated by SYBR green quantitative PCR (qPCR) using prim-
ers listed in S3 Table. DNA libraries were constructed using the MicroPlex Library Preparation
Kit v2 (Diagenode) and sequenced with the Illumina next generation sequencing platform.
ChIP-seq experiments were analysed using Trimmomatic for trimming [47], Bowtie2 for
aligning to the mouse genome (mm9) [48], samtools [49] to remove the aligned reads with a
mapping quality Q30 and MACS2 for peak calling [50] with default narrow peak calling setting
for TFs and broad peak calling setting for histone modification marks. ‘findMotifGenome’
module of the HOMER package was used to detect de novo motif in 200nt summit regions
[24]. Venn diagrams were generated using 200nt peak summits with an overlap of at least 1nt.
GREAT standard association rule settings [25] was used to associate ChIP-seq peaks with
genes and uncover events controlled by TF binding. DiffBind [51] was used to re-center MEIS
and H3K27ac peaks across BA1, BA2 and PBA (S7 Fig) and calculate RPKM values and raw
counts in the re-centered regions. edgeR generalized linear model (GLM) method with TMM
normalization [52] was used to select differential peaks and calculate fold change in MEIS
binding and H3K27ac across BAs used to generate boxplots and scatterplots. Gene expression
CPM values and differential gene expression at E10.5 and E11.5 were derived from [18,30].
ggplot2 package [53] was used to generate CPM values heatmap. GALAXY [54], Bioconductor
GenomicRanges package [55], and Bioconductor ChIPpeakAnno package (https://www.
bioconductor.org/packages//2.10/bioc/html/ChIPpeakAnno.html) were used to intersect,
modify and visualize genomic coordinates. Bioconductor Biostring [56] was used to locate
fixed motif sequences in the binding regions. Distance between HOX and MEIS binding
regions was calculated using GenomicRanges package and plotted with ggplot2. The Kernel
density distribution of MEIS fold enrichment in HOX binding regions vs non-HOX binding
regions were calculated by R kernel density distribution estimation (R core team 2013) and
plotted with ggplot2.
All RNA-seq and ChIP-seq datasets are available on ArrayExpress.
Convolutional neural network models and in silico mutagenesis
MEIS differential sequence features are detected by recently published differential convolu-
tional neural network (CNN) structure [35]. For in silico binding site knockout we trained a
CNN model for multitask regression of MEIS and HOX RPKM binding level. The CNN was
trained by transfer learning, using convolution parameters from a previously published 1-con-
volutional layer MEIS RPKM model [35]. Convolutional filters were transferred to a new
model, which was then trained on a subset of MEIS regions also bound by HOX, to simulta-
neously predict log2RPKM values in 2 replicates of HOXA2 in BA2, 2 from HOXA3 in PBA,
and one replicate of MEIS in BA1, BA2 and PBA. The training data consisted of 6795 regions
of 600nt with HOX binding predicted by MACS2 in any tissue. The regression model was sub-
sequently used to predict the change in RPKM values after binding site erasure. For simulated
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genomic knockout, a 25nt site containing each feature was replaced by random di-nucleotides
from the remaining part of the region and RPKM levels were predicted. Random replacement
was repeated 100 times for each feature, averaging the predicted RPKM change. To select can-
didate features for erasure, MEIS PBA up-binding features were first obtained from the previ-
ously published 3-task parallel model and subsequently filtered. Sites of HOXA3 and GATA
were required to contain consensus motif “TGATNNAT” and “WGATAA” respectively, with
no mismatch allowed. Forkhead sites were selected based on long distinct k-mers, derived
from KSM motif representation method [57], namely exact matches to any of the following
sequences: “AAAATAAACA", "AAAAATAAAC", "AATAAATCAA", "ATNAATCAACA",
"AAATAAACAC", "ATAAATCAAC","GAAAATAAAC", "CAAAATAAAC", "AAAATA
AACT", "AAATAAACAA". These candidate sites were identified within a +/- 250nt window
centred on HOXA3 and GATA6 ChIP-seq peak summits, FE of replicates was combined with
edgeR [52] and a Poisson test was performed as in MACS2 using false discovery rate (FDR)
cutoff = 0.05. Only Forkhead and GATA motifs that did not contain internal matches to
HOX-PBX motif were selected. Subsets of GATA and Forkhead sites located within +/- 100nt
from a HOX-PBX sites were selected for mutagenesis.
Single cell analysis
Single cell transcriptomic data from [28] was retrieved from GEO under accession code
GSE129114. Low-abundance genes were filtered according to [58]. Read counts are normal-
ized according to [59]. Highly variable genes (HVGs) were selected using ‘modelGeneVar’
from scran bioconductor package [60], and used for clustering and dimension reduction.
Clustering was done using Hierarchical clustering function hclust in R with ward.D2 method
[61]. Dimension reduction was performed using with the ‘Rtsne’ function in R.
Electrophoretic mobility shift assays
Probes were made from primers with 5’ ATO700, and purified with QIAGEN PCR purifica-
tion kit (Qiagen). Proteins were generated using TnT Quick Coupled Transcription/Transla-
tion System (Promega) and the following plasmids: pcDNA3-Hoxa2, pcDNA3-Hoxa3,
pcDNA3-Meis2, containing mouse coding sequences for Hoxa2, Hoxa3 and Meis2 (isoform
1), cloned into pcDNA3 (Invitrogen); pcDNA3-PBX1a is a gift from Francesco Blasi. Reactions
(4% Ficoll, 20mM HEPES, 37.5mM KCl, 1mM DTT, 0.1mM EDTA, 2μg Poly dI.dC, 16ng
probe, and 2μl of TNT extracts in total volume of 10μl) were mixed by gentle flicking, and
incubated at room temperature for 12 minutes before being run on 4% acrylamide gel at 70V
in 0.5X TBE. Bands were quantified using ImageJ (version 1.52a). Intensity plots for each lane
were generated by selecting the same region across all the lanes. Individual band intensities
were plotted as histograms areas and quantified by the software. Values in triplicate were aver-
aged and, unless stated otherwise, adjusted to the band intensity of the probe bound by PBX/
MEIS in the absence of any HOX. Corresponding numerical data are provided as supporting
information (data summary).
Luciferase assay
Meis2 and Zfp703 enhancers were amplified from mouse genomic DNA using primers listed
in S3 Table cloned into pCR8/GW/TOPO vector (Life Technologies) and recombined using
the Gateway system (Life Technologies) into pGL4.23-GW (a gift from Jorge Ferrer; Addgene
plasmid # 60323; http://n2t.net/addgene:60323RRID:Addgene_60323). Enhancers were
co-transfected with pcDNA3, pcDNA3-Hoxa2, pcDNA3-Hoxa3, pcDNA3-Meis2, pcDNA3-
PBX1a (described above) and pcDNA3-Hoxd3 generated by GenScript. NIH3T3 cells were
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grown in DMEM (D6429) supplemented with 10% FBS and 5% penicillin/streptomycin, and
seeded in 24-well plates at 100,000 cells in 1ml. Cells were transfected with GeneJuice Trans-
fection Reagent (Novagen), using 250ng luciferase plasmid and 300ng pcDNA3 plasmids per
well. Cells were harvested 24 hours after transfection and luciferase measured using Luciferase
Assay System and the GloMax Multi-Detection System (Promega). Corresponding numerical
data are provided as supporting information (data summary).
Antibody validation
Gateway entry vectors for mouse Hoxb1 and Hoxb2 [62], human HOXA3 and HOXC4 (http://
horfdb.dfci.harvard.edu/hv7/) were used to generate mammalian expression vectors for FLA-
G-HOX (v1899 destination vector) using the gateway technology [63]. Gateway expression
vectors for pExpFLAG-Hoxa1 and pExpFLAG-Hoxa2 are described in [64,65]. HEK293 cells
were grown at 37˚C using DMEM (D6429) supplemented with 10% FBS, 5% penicillin/strep-
tomycin, and 5% L-glutamine. Cells were seeded in 6-well plates at 400,000 cells/well and
transfected 24 hours after plating using 1μg of HOX plasmid constructs and Fugene6 (Pro-
mega) according to the manufacturer’s instructions. Proteins were collected 48 hours after
transfection, boiled in Laemmli buffer, run on SDS-page and visualized using anti-FLAG (M2)
(#F1804, Sigma), HRP-conjugated anti-β-ACTIN (#A3854, Sigma) and anti-Hoxa3 antibody
(1:2000) and HRP-conjugated secondary antibodies.
Co-precipitation experiments
Coding sequences for MEIS1b and MEIS2.1 were cloned in pEnt plasmids, confirmed by
DNA sequencing and used to generate pExp mammalian expression vectors for GST-tagged
proteins with the pDest-GST N-terminal destination vector using the gateway technology [66].
HEK293 cells were transfected as above, using 500ng each of FLAG/GST constructs per well.
Proteins were collected 48 hours after transfection and co-precipitation performed as
described in [62].
Supporting information
S1 Fig. A. Specificity of HOXA3 polyclonal antibody. Western blot using FLAG and HOXA3
antibodies, as indicated. HOXA3 antibody recognizes HOXA3 and does not cross react with
mouse HOXA1, HOXA2 and human HOXB1, HOXB2 and HOXC4. Plasmids containing
HOX-FLAG cDNAs were transfected in HEK293 cells. B. Comparison of HOXA3 ChIP-seq
replicates in E11.5 PBA (FE�10). The replicate with larger genome coverage contains most
(80%) of the second replicate’s peaks and is used in all subsequent analyses. C. Top three most
significant motifs identified in HOXA3 peaks using de novo motif discovery. D. Comparison
of HOXA2 ChIP-seq replicates in E11.5 BA2. The smallest replicate was sequenced using the
Illumina platform and is used for subsequent analysis; it largely (73%) overlaps HOXA2 ChIP-
seq run on the Solid platform (Donaldson et al., 2012). E. Sequence logo of the top three most
significant motifs identified in HOXA2 peaks. F. Frequency of HOX-PBX motifs in HOXA3
and HOXA2 peaks. G. Percentage of HOXA2 (red) and HOXA3 (green) peaks containing
TGATNNAT motifs, with no mismatch (triangles) or 1nt mismatch (circles) allowed. Increas-
ing numbers of top HOX peaks, ordered by decreasing FE, are plotted on the x axis. For both
HOXA2 and HOXA3, the percentage of peaks containing a perfect match (no mismatch) to
TGATNNAT decreases with relaxing FE. The opposite trend is observed for the distribution
of TGATNNAT motifs with 1nt mismatch allowed. H, Enrichment of HOXA2 regulated genes
(red fraction) in the top biological processes and mouse phenotypes identified by GREAT; the
remaining fraction corresponds to genes associated with HOXA2 peaks, but not significantly
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dysregulated in HOXA2 mutant embryos. The number of genes in each category and the cor-
responding p value (Fisher’s exact test) are indicated.
(PDF)
S2 Fig. A. Percentage of TGATNNAT variants in top 250 or in top 250 to 2000 HOXA2 and
HOXA3 peaks, as indicated. HOX-selective binding is more evident in the fraction of high-
confidence peaks, suggesting that analysis of whole ChIP-seq experiments may mask effective
HOX specificity. B. Distance between TGATNNAT (HOX-PBX) and TGACA (MEIS) in top
250 HOXA2 (red) and HOXA3 (green) peaks. Most TGACA occur at<20 nt from a
HOX-PBX site. C. Quantification of MEIS/PBX/HOX (trimeric) complexes binding to the
wild-type and mutant Sulf2 probe. Complexes are colour-coded according to the presence of
HOXA2 (red boxes) and HOXA3 (green boxes). Values (raw data) were obtained from three
independent experiments. Binding of HOXA3 to the wild-type Sulf2 probe is significantly
higher relative to HOXA2, while no significant difference is detected between HOXA3 and
HOXA2 binding to the Sulf2 mutant probe. One-way ANOVA with post-hoc Tukey HSD
(Honestly Significant Difference) test: � = p<0.05.
(PDF)
S3 Fig. A. UCSC tracks of HOXA2, HOXA3, PBX, MEIS binding and H3K27 acetylation pro-
files in BA2 (red) and PBA (green) at the Zfp703 locus. Strong HOX and TALE binding is
observed in both tissues, with higher acetylation levels in BA2. B. Luciferase activity driven by
Zfp703 enhancer co-transfected with Hoxa2 (red bar), Hoxa3 (green bar), Hoxa2-a3HD (red
empty bar), Hoxa3-a2HD (green empty bar), Meis2 and Pbx1a (grey bar) expression vectors,
alone and in combination, in NIH3T3 cells. Addition of MEIS/PBX amplifies the difference in
HOXA2 and HOXA3 activation abilities. Changing the HOX-PBX site (shown in C) reduces
HOX-TALE activation to the levels observed with TALE alone (empty bars). Values represent
fold activation over basal enhancer activity and are presented as the average of at least two
independent experiments, each performed in triplicate. Error bars represent the SEM. One-
way ANOVA with post-hoc Tukey HSD test: � = p<0.05; ��� = p<0.0005. C. Sequence of
Zfp703 wild-type and mutant enhancer encompassing HOX-PBX and MEIS sites. HOX-PBX
and MEIS motifs are underlined. Nucleotide substitution in the HOX-PBX site are shown in
red. D. Luciferase activity driven by Meis2 enhancer co-transfected with Hoxa2 (red bar),
Hoxa3 (green bar), Hoxd3 (green bar), Meis2 and Pbx1a, alone and in combination. When co-
expressed with MEIS and PBX, HOXA2 shows higher activation capacity than HOX paralog 3.
Statistical analysis was performed as in B. EF. HOXA2 (E, red arrow) and HOXA3 (F, green
arrow) weakly bind the Meis2 probe. MEIS and PBX bind DNA together (black arrow).
HOXA2 (E) or HOXA3 (F) do not bind the Meis2 probe with either MEIS or PBX alone. Addi-
tion of HOXA2 and HOXA3 to MEIS/PBX results in a trimeric protein complex (arrowheads
in E and F). G. Quantification of MEIS/PBX and HOX binding to Meis2 probe. Binding of
MEIS/PBX (dimeric) and MEIS/PBX/HOX (trimeric) complexes is expressed as relative per-
centage to PBX/MEIS binding to Meis2 probe in the absence of any HOX. Dimeric and tri-
meric complexes are colour-coded according to the presence of HOXA2 (red boxes),
HOXA2-A3HD (dark red boxes), HOXA3 (green boxes) and HOXA3-A2HD (dark green
boxes). Values were obtained from at least three independent experiments. HOXA2 binds the
Meis2 probe with higher affinity with PBX/MEIS, relative to HOXA3. Accordingly, HOXA2
shifts more of the PBX/MEIS dimer into a trimeric complex, relative to HOXA3. A similar
behaviour is observed with chimeric HOX (��� = p<0.0005; � = p<0.05, one-way ANOVA
with post-hoc Tukey HSD test). HI. Quantification of HOX/MEIS/PBX trimeric (H) and
MEIS/PBX dimeric (I) binding to Meis2 probe shown in Fig 3H. Binding of MEIS/PBX
(dimeric) and MEIS/PBX/HOX (trimeric) complexes is expressed as relative percentage to
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PBX/MEIS binding to Meis2 probe in the absence of any HOX. The total HOX dose is unvar-
ied and corresponds to 100%; HOXA2 and HOXA3 are translated alone and co-translated
with each other at different ratios, as follows: 100% HOXA2; 75% HOXA2 + 25% HOXA3;
50%HOXA2 + 50% HOXA3; 25% HOXA2 + 75% HOXA3; 100% HOXA3. Colour coded %
are indicated below the x-axis; HOXA2 is red and HOXA3 is green. HOXA2 forms a signifi-
cantly stronger trimeric complex than HOXA3 at all comparable concentrations, except 25%
(difference not significant). Values were obtained from three independent experiments. I.
PBX/MEIS complex is significantly reduced in the presence of all HOX. HOXA2 causes a sig-
nificantly greater reduction than HOXA3. One-way ANOVA with post-hoc Tukey HSD test: �
= p<0.05; ��p<0.005; ��� = p<0.0005. J. Same experiment as in Fig 3G, run on a lower per-
centage gel to resolve slower retarded bands. No apparent HOXA2/HOXA3/PBX/MEIS com-
plexes can be detected as slower bands above HOXA3 trimeric complex. K. Mutations in
MEIS and HOX/PBX recognition sites affect MEIS/PBX and HOX/MEIS/PBX binding to
Meis2 probe. Arrow and arrowheads indicate dimeric and trimerix complexes, respectively;
asterisks mark lanes containing a detectable trimeric complex. Representative gels are shown;
each independent gel contains PBX/MEIS binding to Meis2 wild-type probe as a reference.
Mutant probes are indicated on the top and named as in Fig 3H; quantifications of MEIS/PBX
dimers are shown in Fig 3I.
(PDF)
S4 Fig. A. tSNE (T-distributed Stochastic Neighbour Embedding) of E10.5 post-otic cranial
neural crest single cell RNA-seq (Soldatov et al. 2019) clusters cells into four main clusters. B.
Two clusters (green and purple ovals in AB) exhibit high-expression of Hoxa2 and Hoxa3.
Count of cell expressing Hoxa2 and Hoxa3 in the green and purple clusters shows that the
majority of cells co-express Hoxa2 and Hoxa3, more than what is expected by chance (Fisher
exact test). C. Quantification of HOX/MEIS/PBX binding to Meis2 probe shown in Fig 4E.
Each HOX is co-translated with PBX/MEIS alone or with the other HOX. The highest HOX
dose corresponds to 100%; HOXA2 (red) is translated at progressively decreasing levels, either
alone, or co-translated with progressively increasing levels of HOXA3 (green) as indicated on
the x-axis. At 50% and 25% levels, HOXA2 forms a significantly stronger trimeric complex
(red arrow) on its own than when HOXA3 is added.
(PDF)
S5 Fig. A. Whole Venn diagram of HOXA3, MEIS and PBX binding overlap, cropped in Fig
5A. Most MEIS and PBX peaks do not overlap with any HOXA3 peaks. B-D. Kernel density
plots of MEIS peaks relative to FE. MEIS binding is sorted into peaks not overlapping HOX
(lighter colour) and peaks overlapping HOX as indicated (darker colour). HOX and MEIS
ChIP-seq in mouse embryonic stem cells (HOXA1), BA2 (HOXA2) and hematopoietic stem
cells (HOXA9) were used in this analysis.
(PDF)
S6 Fig. A. GREAT analysis of MEIS peaks higher in BA2 (relative to PBA, red) and PBA (rela-
tive to BA2, green). Fold change�5 across BAs is used as a cutoff. Differential MEIS peaks are
associated with genes involved in different biological processes (top 10 categories are shown).
BC. Fold change (PBA versus BA2) in MEIS binding and H3K27ac levels at HOX and GATA
peaks. B. HOXA3 binding in PBA (green) and HOXA2 binding in BA2 (red) is associated with
increased MEIS binding and H3K27ac in the corresponding tissues. C. Similarly, GATA6
binding in PBA is associated with increased MEIS and H3K27ac in PBA. DE. HOMER motif
search in the vicinity of HOX/PBX sequence features identified by CNN (+/-100 nt around
TGATNNAT, as shown in D) identifies enrichment of Forkhead motifs in MEIS higher PBA.
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Other enriched flanking motifs include MEIS and HD motifs. F. Example of HOX and Fork-
head features, identified by CNN in a HOX- bound region. The RPKM feature tracks show
combined RPKM change caused by mutating each nucleotide to its alternatives. Features of
two experimental replicates for HOXA2 in BA2 and two replicates of HOXA3 in PBA are pre-
dicted by a jointly trained multitask model, trained by transfer learning from a MEIS RPKM
model. Below, normalised cross-correlation of region sequence with HOX and Forkhead posi-
tion weight matrix (PWM) obtained by k-mer counting is shown. Nucleotides in HOX and
Forkhead motifs show increased sensitivity to perturbation, compared to their surrounding
sequences. G. Motifs occurrence in top 250 HOXA2 and HOXA3 peaks (200 nt summits). Fre-
quencies of single and co-occurring motifs are expressed as percentages and colour-coded in
the bar plot. Square brackets indicate bHLH (CATCTG) in HOXA2 and Forkhead (TACAAA)
in HOXA3 peaks. Motif frequency is calculated using IUPAC letters, as indicated.
(PDF)
S7 Fig. Identification of MEIS differential binding. MACS peaks from MEIS ChIP-seq
experiments in BA1, BA2 and PBA with replicates were recentered using DiffBind (see meth-
ods), and pairwise fold changes and differential binding regions were computed by edgeR as
described (Phuycharoen et. al. 2019). Pairwise differential regions were combined into MEIS
BA1 up, BA1 down, BA2 up, BA2 down, PBA up, and PBA down regions. Differential
sequence motifs were detected as described (Phuycharoen et. al. 2019). Differential H3K27ac
regions and fold changes were computed in the same manner.
(PDF)
S1 Table. Regions bound by Hoxa3 in PBA, Fold Enrichment (FE)>10.
(CSV)
S2 Table. Regions bound by Hoxa2 in BA2, FE>10.
(CSV)
S3 Table. List of primers used in this study.
(DOCX)
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